Home » Stocks » HSDT

Helius Medical Technologies, Inc. (HSDT)

Stock Price: $15.75 USD -0.33 (-2.05%)
Updated Jul 23, 2021 4:00 PM EDT - Market closed
Market Cap 36.50M
Revenue (ttm) 539,000
Net Income (ttm) -12.74M
Shares Out 2.04M
EPS (ttm) -8.57
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day July 23
Last Price $15.75
Previous Close $16.08
Change ($) -0.33
Change (%) -2.05%
Day's Open 15.82
Day's Range 15.51 - 15.92
Day's Volume 21,486
52-Week Range 11.00 - 796.25

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

NEWTOWN, Pa., July 12, 2021 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (TSX:HSM) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today announc...

1 week ago - GlobeNewsWire

NEWTOWN, Pa., July 08, 2021 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (TSX:HSM) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today announc...

2 weeks ago - GlobeNewsWire

Company Selected to Receive the “Pioneer in Technology Award” Company Selected to Receive the “Pioneer in Technology Award”

2 weeks ago - GlobeNewsWire

NEWTOWN, Pa., June 30, 2021 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (NASDAQ:HSDT) (TSX:HSM) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today announc...

3 weeks ago - GlobeNewsWire

NEWTOWN, Pa., June 08, 2021 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (TSX:HSM), (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today announ...

1 month ago - GlobeNewsWire

NEWTOWN, Pa., June 02, 2021 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (TSX:HSM) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today announc...

1 month ago - GlobeNewsWire

NEWTOWN, Pa., May 17, 2021 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (TSX:HSM) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today reported...

2 months ago - GlobeNewsWire

NEWTOWN, Pa., April 15, 2021 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (TSX:HSM) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today announ...

3 months ago - GlobeNewsWire

NEWTOWN, Pa., April 07, 2021 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (NASDAQ:HSDT) (TSX:HSM) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today announ...

3 months ago - GlobeNewsWire

First and only tongue-delivered neuromodulation therapy provides new treatment option for U.S. patients living with gait deficit due to symptoms from multiple sclerosis First and only tongue-delivered n...

3 months ago - GlobeNewsWire

NEWTOWN, Pa., March 17, 2021 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (TSX:HSM) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today announ...

4 months ago - GlobeNewsWire

NEWTOWN, Pa., March 17, 2021 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (TSX:HSM) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today announ...

4 months ago - GlobeNewsWire

NEWTOWN, Pa., March 10, 2021 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (TSX:HSM) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today report...

4 months ago - GlobeNewsWire

NEWTOWN, Pa., Feb. 02, 2021 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (NASDAQ:HSDT) (TSX:HSM) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today announc...

5 months ago - GlobeNewsWire

NEWTOWN, Pa., Feb. 01, 2021 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (TSX:HSM) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, announced tod...

5 months ago - GlobeNewsWire

NEWTOWN, Pa., Jan. 20, 2021 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (TSX:HSM) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today provide...

6 months ago - GlobeNewsWire

The Company's Stock Will Continue to be Listed and Traded on The Nasdaq Stock Market

6 months ago - GlobeNewsWire

NEWTOWN, Pa., Jan. 15, 2021 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (TSX:HSM) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today announc...

6 months ago - GlobeNewsWire

Submits formal response to the U.S. Food and Drug Administration's request for additional information Submits formal response to the U.S. Food and Drug Administration's request for additional information

6 months ago - GlobeNewsWire

NEWTOWN, Pa., Jan. 05, 2021 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (TSX:HSM) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, is issuing th...

6 months ago - GlobeNewsWire

NEWTOWN, Pa., Jan. 04, 2021 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (TSX:HSM) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today announc...

6 months ago - GlobeNewsWire

NEWTOWN, Pa., Dec. 31, 2020 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (TSX:HSM) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, announced tod...

6 months ago - GlobeNewsWire

Helius Medical Technologies' (HSDT) Management on Q3 2020 Results - Earnings Call Transcript

8 months ago - Seeking Alpha

NEWTOWN, Pa., Nov. 05, 2020 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (TSX:HSM) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today announc...

8 months ago - GlobeNewsWire

New clinics increase access to PoNS Treatment in population-dense areas across Canada New clinics increase access to PoNS Treatment in population-dense areas across Canada

8 months ago - GlobeNewsWire

NEWTOWN, Pa., Nov. 02, 2020 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (NASDAQ:HSDT) (TSX:HSM) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today announc...

8 months ago - GlobeNewsWire

NEWTOWN, Pa., Oct. 26, 2020 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (TSX:HSM) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, announced tod...

8 months ago - GlobeNewsWire

NEWTOWN, Pa., Oct. 21, 2020 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (TSX:HSM) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, announced tod...

9 months ago - GlobeNewsWire

NEWTOWN, Pa., Oct. 19, 2020 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (TSX:HSM) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today announc...

9 months ago - GlobeNewsWire

NEWTOWN, Pa., Oct. 14, 2020 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (NASDAQ: HSDT) (TSX: HSM) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today annou...

9 months ago - GlobeNewsWire

Leading Multiple Sclerosis Experts to Inform U.S. Launch Planning and Market Access Strategies Leading Multiple Sclerosis Experts to Inform U.S. Launch Planning and Market Access Strategies

9 months ago - GlobeNewsWire

NEWTOWN, Pa., Sept. 08, 2020 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (NASDAQ:HSDT) (TSX:HSM) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today anno...

10 months ago - GlobeNewsWire

NEWTOWN, Pa., Aug. 31, 2020 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (TSX:HSM) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today annou...

10 months ago - GlobeNewsWire

NEWTOWN, Pa., Aug. 25, 2020 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (NASDAQ:HSDT) (TSX:HSM) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today annou...

10 months ago - GlobeNewsWire

Helius Medical Technologies, Inc. (HSDT) CEO Phil Deschamps on Q2 2020 Results - Earnings Call Transcript

11 months ago - Seeking Alpha

Helius Medical Technologies, Inc. (HSDT) delivered earnings and revenue surprises of 33.33% and 33.00%, respectively, for the quarter ended June 2020.

11 months ago - Zacks Investment Research

NEWTOWN, Pa., Aug. 12, 2020 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (TSX:HSM) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today repor...

11 months ago - GlobeNewsWire

NEWTOWN, Pa., Aug. 10, 2020 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (NASDAQ:HSDT) (TSX:HSM) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today annou...

11 months ago - GlobeNewsWire

Helius Medical Technologies, Inc. (HSDT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report.

11 months ago - Zacks Investment Research

NEWTOWN, Pa., Aug. 06, 2020 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (NASDAQ:HSDT) (TSX:HSM) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today annou...

11 months ago - GlobeNewsWire

NEWTOWN, Pa., July 14, 2020 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (NASDAQ:HSDT) (TSX:HSM) (“Helius” or the “Company”), announced the dismissal of a putative shareholder class action in...

1 year ago - GlobeNewsWire

NEWTOWN, Pa., May 12, 2020 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (NASDAQ:HSDT) (TSX:HSM) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today announ...

1 year ago - GlobeNewsWire

Helius Medical Technologies, Inc. (HSDT) CEO Phil Deschamps on Q1 2020 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

122 Subject, Multicenter, Double-Blind, Randomized, Clinical Trial Finds PoNS Treatment™ Provides Significant Improvement in Balance and Gait Deficits for Individuals Who Have Experienced a Mild-to-Mode...

1 year ago - GlobeNewsWire

122 Subject, Multicenter, Double-Blind, Randomized, Clinical Trial Finds PoNS Treatment™ found Significant Improvement in Balance and Gait Deficits for Individuals Who Have Experienced a Mild-to-Moderat...

1 year ago - GlobeNewsWire

NEWTOWN, Pa., April 22, 2020 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (NASDAQ: HSDT) (TSX: HSM) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today an...

1 year ago - GlobeNewsWire

NEWTOWN, Pa., March 24, 2020 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (NASDAQ:HSDT) (TSX:HSM) (“Helius” or the “Company”), today announced that its Canadian Class II license amendment app...

1 year ago - GlobeNewsWire

NEWTOWN, Pa., March 18, 2020 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (TSX:HSM) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, announced ...

1 year ago - GlobeNewsWire

Helius Medical Technologies, Inc. (HSDT) CEO Phil Deschamps on Q4 2019 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

Expands Access to PoNS Treatment™ in the Greater Toronto Area and Southwestern Ontario Expands Access to PoNS Treatment™ in the Greater Toronto Area and Southwestern Ontario

1 year ago - GlobeNewsWire

About HSDT

Helius Medical Technologies, Inc., a neurotechnology company, focuses on developing, licensing, and acquiring non-invasive technologies for the treatment of symptoms caused by neurological disease or trauma. Its product, Portable Neuromodulation Stimulator (PoNS), is a non-implantable investigational medical device intended for use as a short term treatment of gait deficit due to symptoms from multiple sclerosis and balance deficit due to mild-to-moderate traumatic brain injury, as well as to be used in conjunction with supervised therapeutic e... [Read more...]

Industry
Medical Devices
CEO
Philippe Deschamps
Employees
19
Stock Exchange
NASDAQ
Ticker Symbol
HSDT
Full Company Profile

Financial Performance

In 2020, HSDT's revenue was $661,000, a decrease of -55.82% compared to the previous year's $1.50 million. Losses were -$14.13 million, 44.5% more than in 2019.

Financial Statements